These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. Kasid A; Bell GI; Director EP J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414 [TBL] [Abstract][Full Text] [Related]
45. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716 [TBL] [Abstract][Full Text] [Related]
46. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Alamartine E; Sabido O; Berthoux F Nephrol Dial Transplant; 1994; 9(10):1456-61. PubMed ID: 7529381 [TBL] [Abstract][Full Text] [Related]
47. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804 [TBL] [Abstract][Full Text] [Related]
48. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587 [TBL] [Abstract][Full Text] [Related]
49. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors. Miller JS; Verfaillie C; McGlave P Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991 [TBL] [Abstract][Full Text] [Related]
50. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii. Subauste CS; Dawson L; Remington JS J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415 [TBL] [Abstract][Full Text] [Related]
51. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions. Chao TY; Hwang WS; Yeh MY Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448 [TBL] [Abstract][Full Text] [Related]
52. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Nio Y; Zighelboim J; Berek JS; Bonavida B Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317 [TBL] [Abstract][Full Text] [Related]
53. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458 [TBL] [Abstract][Full Text] [Related]
55. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells. Koberda J; Bergmann L; Mitrou PS; Hoelzer D J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699 [TBL] [Abstract][Full Text] [Related]
56. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. Fox BA; Rosenberg SA Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456 [TBL] [Abstract][Full Text] [Related]
57. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells]. Ebihara T; Koyama S Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266 [TBL] [Abstract][Full Text] [Related]
58. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193 [TBL] [Abstract][Full Text] [Related]
59. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Verfaillie C; Kay N; Miller W; McGlave P Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114 [TBL] [Abstract][Full Text] [Related]
60. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2. Akporiaye ET; Barbieri CA; Stewart CC; Bender JG J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]